The impact of autoimmune cytopenias on the clinical course and survival of Hodgkin lymphoma
- PDF / 1,443,013 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 82 Downloads / 157 Views
ORIGINAL ARTICLE
The impact of autoimmune cytopenias on the clinical course and survival of Hodgkin lymphoma László Imre Pinczés1,2 · Roxána Szabó1 · Zsófia Miltényi1,2 · Árpád Illés1,2 Received: 25 May 2020 / Revised: 1 September 2020 / Accepted: 1 October 2020 © Japanese Society of Hematology 2020
Abstract The characteristics of autoimmune cytopenias (AICP) associated with Hodgkin lymphoma (HL) are not thoroughly defined. We retrospectively assessed the clinical features of HL-associated AICPs in 563 HL patients diagnosed over a period of 28 years. We identified 8 cases of autoimmune hemolytic anemia (AIHA) and 8 cases of autoimmune thrombocytopenia among 14 patients altogether. Four (26%) AICPs were present at lymphoma diagnosis, while 11 (74%) cytopenias occurred during follow-up after first-line therapy. The overall incidence of HL-associated AICPs was 2.8%. Nine (75%) cytopenias responded to intravenous steroids. Seven (46%) AICPs led to the diagnosis of HL, indicated a relapse, or revealed secondary malignancies. AIHAs and AICPs altogether were more likely to develop in patients with advanced-stage HL (p = 0.010 and p
Data Loading...
